NCT05976763 2026-03-04
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
Clinical Trials
21 trialsNCT03267433 2026-03-02
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT02972840 2026-02-18
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT04002297 2025-09-26
MANGROVE
BeiGene
Phase 3 Active not recruiting
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT01996865 2025-07-10
MAGNIFY
Celgene
Phase 3 Completed
NCT01776840 2025-07-08
A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
Janssen Research & Development, LLC
Phase 3 Completed
NCT06363994 2024-12-27
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
InnoCare Pharma Inc.
Phase 3 Recruiting
NCT01456351 2024-08-22
Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab
University of Giessen
Phase 3 Completed
NCT06496308 2024-07-11
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
Ruijin Hospital
Phase 3 Recruiting
NCT04849715 2022-04-29
CITADEL-310
Incyte Corporation
Phase 3 Withdrawn
NCT00052936 2021-05-18
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT00003280 2019-05-15
Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma
Swiss Cancer Institute
Phase 3 Completed
NCT00722137 2018-07-12
Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma
Takeda
Phase 3 Completed
NCT00921414 2018-04-27
Mantel Cell Lymphoma Efficacy of Rituximab Maintenance
French Innovative Leukemia Organisation
Phase 3 Completed
NCT00877006 2018-02-05
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 3 Completed
NCT02858258 2017-12-19
ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma
European Mantle Cell Lymphoma Network
Phase 3 Recruiting
NCT00209209 2017-03-07
MCLelderly
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT01449344 2017-03-07
(R-HAD)
European Mantle Cell Lymphoma Network
Phase 3 Unknown
NCT01933711 2016-05-13
Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma
University Hospital Heidelberg
Phase 3 Unknown
NCT00028717 2013-09-17
Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 3 Unknown